On Jan. 24, 2019, Pascal Biosciences announced the testing of cannabinoids in human subjects for its immune stimulatory program in cancer. Furthermore, the Company filed an international patent application to protect this work for future therapeutic indications.

More than 375 cannabinoids from numerous sources were examined, including natural cannabinoids from Cannabis (known as phytocannabinoids), synthetic cannabinoids prepared by chemists, and endocannabinoids naturally found in the human body. Specific natural cannabinoids have been identified that have potent activity in immune assays and also have a good safety profile.